Healio: Potassium Binder Helps Optimize Spironolactone Use in Patients with HF, Hyperkalemia Risk

A potassium binder helped patients with heart failure (HF) who have or are at high risk for hyperkalemia stay on spironolactone at an optimal dose, but showed a signal of HF hospitalization risk, researchers reported.

For the REALIZE-K trial, presented at the American Heart Association Scientific Sessions and simultaneously published in the Journal of the American College of Cardiology, Mikhail Kosiborod, MD, FACC, FAHA, cardiologist and vice president of research at Saint Luke’s Mid America Heart Institute and professor of medicine at the University of Missouri-Kansas City School of Medicine, and colleagues randomly assigned 203 patients with HF with reduced ejection fraction and hyperkalemia or elevated risk for it to spironolactone plus the potassium binder sodium zirconium cyclosilicate or to spironolactone plus placebo.

Read the full Healio article: Potassium Binder Helps Optimize Spironolactone Use in Patients with HF, Hyperkalemia Risk

Related Content

Nov. 12, 2024

Medical Xpress: Bystander CPR up to 10 Minutes After Cardiac Arrest May Protect Brain Function
New research shows the sooner a lay rescuer starts CPR on a person having a cardiac arrest at home or in public, the better the chances of saving the person's life and protecting their brain function.
Nov. 8, 2024

Medical Xpress: Transcatheter Tricuspid Valve Replacement Aids Tricuspid Regurgitation
Dr. Suzanne Arnold and colleagues performed an in-depth analysis of the health status of patients enrolled in the TRISCEND II pivotal trial.
Oct. 15, 2024

Healio: Wegovy Improves Exercise Function in Obesity-Related Heart Failure with Concomitant Weight Loss
A secondary analysis of the pooled STEP-HFpEF and STEP-HFpEF DM trials showed the greatest improvements in those with the most weight loss at 52 weeks.